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Non-metastatic glycoprotein melanoma protein B (GPNMB), also known as osteoactivin (OA) is
expressed in a wide array of tumors and represents an emerging target for drug development.
In this study, we investigated the role of GPNMB/OA in the progression of human metastatic
DU145 and PC3 prostate cancer cells.
GPNMB/OA contribution in PCa malignant phenotype has been analyzed by small interfering
RNA-induced GPNMB/OA silencing. We found that following GPNMB/OA silencing the migration
capability of both DU145 and PC3 cells, evaluated by using in vitro invasivity assay, as well as the
metalloproteinases MMP-2 and MMP-9 activity were equally strongly inhibited. By contrast
knocking down GPNMB/OA weakly attenuated cell proliferation rate of DU145, an effect that
paralleled with an increase number of apoptotic cells. However, PC3 cell growth seems to be not
affected by GPNMB/OA. Together, these data reveal that GPNMB/OA acts as a critical molecular
mediator promoting the acquisition of the more aggressive, pro-metastatic phenotype distinctive
of human DU145 and PC3 cell lines.
& 2014 Elsevier Inc. All rights reserved.ed.
B, non-metastatic glycoprotein melanoma protein B; OA, osteoactivin; MMPs, metallopro-
etalloproteinases; NGF, Nerve Growth Factor; Q-RT-PCR, quantitative real time-PCR; siRNA,
ignal-regulated kinases 1 and 2; rt, room temperature; o/n, overnight
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Prostate cancer (PCa) is the most frequently occurring tumor in men
and the second leading cause of male cancer deaths both in Europe
and in the United States [1]. Its incidence is increasing in the Western
societies as population age; competing causes of death are more
controlled and newer screening and detection tools are broadly
implemented. At the beginning, the disease is androgen-dependent
and can be treated with surgery and/or hormone therapy [2].
Unfortunately, beneﬁts of the androgen-deprivation therapy are
counteracted by the emergence of castration-resistant prostate cancer
(CRPC), that is usually fatal. A remarkable aspect of CRPC is the
reactivation of androgen receptor (AR) signaling, that is followed by
an increase of AR-regulated genes such as the prostate speciﬁc
antigen [3]. The role of the AR axis in CRPC is indeed increasingly
recognized: castration-resistant tumors, even in the presence of very
low levels of circulating androgens, are frequently still dependent on
functional ARs. Several molecular mechanisms have been proposed to
explain this phenomenon, such as an increased expression and/or
mutations of the AR mRNA and protein, changes in the expression of
AR coregulators, local increased expression of steroidogenic enzymes
or ligand-independent AR signaling (reviewed in [4]). Thus, in CRPC,
AR can assume a role of lineage oncogene [4,5].
Besides the AR axis, other growth factor pathways have been
shown to be dysregulated in PCa development and progression
[6,7]. Among these, we drew our attention on Nerve Growth
Factor (NGF) [8]. Evidence indicates that the NGF pathway, which
is crucial for the physiological prostate epithelial cell growth and
differentiation, is involved in PCa carcinogenesis. The observation
that NGF production is progressively lost in PCa advancement and
that the decreasing expression of the NGF receptor p75NGFR in PCa
cells correlates with cancer degeneration strongly supports this
hypothesis [8]. On this line, we demonstrated that human PCa cell
lines DU145 and PC3, when exposed to exogenous NGF, differ-
entiate into a phenotype characterized by the re-expression of
p75NGFR, functionally active ARs and the reduction of telomerase
activity [9,10]. This experimental model of NGF-induced reduction
of PCa cell malignant phenotype was used to identify novel
molecular targets involved in cancer progression. In particular,
the gene-expression proﬁling technique applied on DU145 cell
line allowed the identiﬁcation of clusters of genes involved in
proliferation, invasion and metastasis, speciﬁcally modiﬁed by
NGF exposure [11]. Among genes involved in invasion and
metastasis, our attention was drawn by the non-metastatic
glycoprotein melanoma protein B (GPNMB) gene, encoding a type
1 transmembrane 572 amino acid protein [12]. GPNMB, also
known as osteoactivin (OA), dendritic cell–heparin integrin
ligand, or hematopoietic growth factor inducible neurokinin-type,
is expressed in a wide array of normal tissue, such as bone,
hematopoietic system and skin, where it inﬂuences cell prolifera-
tion, adhesion, differentiation and synthesis of extracellular
matrix proteins [13]. Furthermore, GPNMB/OA overexpression
has been linked to several aggressive cancers, including uveal
and cutaneous melanoma [14,15], hepatocellular carcinoma [16],
glioma [17,18] and breast cancer (BC) [19,20]. Indeed, the GPNMB/
OA ectopic overexpression enhances the cell invasive phenotype
both in vitro and in vivo [16,17,19,21]. In line with this, the role of
GPNMB/OA in the human PCa, in particular in the advanced PCa,
characterized by metastatic dissemination to liver, lung, brain andbone and currently incurable, has been recently investigated with
conﬂicting results [22,23].
Against this background, we used the human metastatic PCa
cell lines DU145 and PC3 to investigate the role of GPNMB/OA in
PCa malignant progression. We clearly established that NGF
treatment of PCa cells is associated with decreased levels of
GPNMB/OA expression, supporting the role of GPNMB/OA in
promoting the malignant phenotype. By using a siRNA approach,
we found that the reduction of GPNMB/OA expression slightly
inﬂuenced the rate of DU145 and PC3 cell proliferation but deeply
affected their aggressive phenotype, abrogating their in vitro
invasive potential. This phenomenon may ﬁnd its molecular
determinant in the reduced expression and function of the
metalloproteinases MMP-2 and MMP-9, key molecules intimately
involved in prostate tumor progression [24–27]. Our data indicate
that GPNMB/OA can act as a promoter of the progression of
human PCa into a more aggressive and metastatic phase.Materials and methods
Cell culture
PC3 and DU145 cells were purchased from the American Type
Culture Collection (ATCC) (LGC Promochem, Sesto San Giovanni,
MI, Italy) and maintained in culture as suggested by ATCC. Media,
supplements were purchased from Euroclone (Pero, Mi, Italy).
Cells were treated as previously described [9,10]. Human recom-
binant NGF was purchased from Sigma-Aldrich Italia (Milano,
Italy). Conditioned media were obtained by culturing DU145 and
PC3 cells (106 cells/1 ml) in serum-free medium for 24 h. Media
were then centrifuged at 1500g for 5 min at 4 1C, the debris was
discarded and media were lyophilized and stored at 20 1C until
use. PCS-440-010 human primary prostate epithelial cells were
purchased from ATCC and cultured as suggested.
RNA extraction, reverse transcription and quantitative
RT-PCR (Q-RT-PCR)
Total RNA was extracted from 107 cells using the RNAeasy kit
(Qiagen, Milano, Italia) and 1 μg was transcribed into cDNA, using
murine leukemia virus reverse transcriptase (Promega Italia,
Milano, Italy). Gene expression was evaluated by Q-RT-PCR
(iCycler iQ real-time PCR detection system, BioRad Laboratories,
Milano, Italy), using the SYBR Green as ﬂuorochrome, as described
[11]. Sequences of sense and anti-sense oligonucleotide primers
of GPNMB/OA were S: 5'-CTGTGAACACAGCCAATGTG-3'; AS: 5'-
ATGGGGAGATCTTTGAGGAA-3' and of human β-actin were S: 5'-
TCTTCCAGCCTTCCTTCCCTG-3'; AS: 5'-CAATGCCAGGGTACATG-
GTG-3'. Reactions were performed under the following condi-
tions: 1 cycle 95 1C for 10 min, 40 cycles at 95 1C for 15 s, and
60 1C for 1 min. Differences of the threshold cycle Ct values
between the β-actin housekeeping gene and GPNMB/OA gene
(ΔCt) were then calculated, as an indicator of difference in the
amount of mRNA expressed.
Indirect immunoﬂuorescence
Control and NGF-treated DU145 and PC3 cells were plated (105 cells/
well) in tissue culture Petri dishes (3.5 cm diameter) containing
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coverslips were ﬁxed in 95% ethanol for 10 min and 50% ethanol
for 5 min, then washed in phosphate buffer solution (PBS). Endo-
genous peroxidases were inactivated for 20 min with 0.03%
H2O2 solution. Cells were permeabilized with a solution containing
0.2% Triton X-100 for 60 min at room temperature and then
incubated overnight at 4 1C with a primary anti-GPNMB/OA mono-
clonal antibody (clone 303822, MAB25501, R&D Systems, Minnea-
polis, USA), raised in mouse and directed against the aa 22-486
sequence of the human protein (0.4 mg/ml). After extensive washes,
the Alexa Fluor488 anti-mouse secondary antibody (Life Technolo-
gies, Milano, Italy) (5 mg/ml ﬁnal concentration) was applied for
60 min at room temperature. Coverslips were mounted using the
FluorPreserve™ Reagent and cell staining was detected using the
IX51 inverted ﬂuorescence microscope (Olympus, Tokyo, Japan)
(magniﬁcation 200 ).
GPNMB/OA gene silencing by RNA interference
A pool of four small interfering RNA (siRNA) duplexes targeting
different regions of the human GPNMB/OA gene (si-GPNMB/OA) and
non-targeting scrambled negative control siRNA (si-scrambled)
duplex were used (ON-TARGETplus SMARTpool, Dharmacon). The
si-GPNMB/OA sequences (according to the manufacturer's nomencla-
ture) were siRNA-9: 5'-CCAGAAGAACGAUCGAAAU-3'; siRNA-10: 5'-
UGCAAGAAGAGGCGGCGGGAUA-3'; siRNA-11: 5'-AUAUAACAUU-
UGCGGUGAA-3'; siRNA-12: 5'-GGAAUUUCAUCUCUACGUCUU-3'.
DU145 and PC3 PCa cells were transfected with different concentra-
tions (10–100 nM) of si-GPNMB/OA or si-scrambled pool using the
INTERFERin™ siRNA transfection reagent (Polyplus-Transfection,
Euroclone). Brieﬂy, cells (2104) were seeded in each well of
12-well cell culture plates and incubated for 24 h. After 24 h,
transfection complexes were prepared using si-GPNMB/OA, si-
scrambled, siRNA transfection reagent and transfection medium,
according to the manufacturer's instructions and delivered to cells.
Western blot
Untreated, si-scrambled- and si-GPNMB/OA-treated cells as well
as the 24-h conditioned media for each treatment were collected.
Both cell pellets and conditioned media were lysed in ice-cold
buffer (20 mM Tris–HCl pH 7.4, 5 mM EDTA, 2 mM EGTA, 0.5%
sodium deoxycholate, 0.1% SDS, 1% NP-40 and a complete set of
protease inhibitors (Roche, Milano, Italy)). Equal amount of
protein for each sample was separated by electrophoresis on a
4–12% NuPAGE Bis–Tris Gel System (Life Technologies, Milano,
Italy) and electroblotted to a nitrocellulose membrane, following
the manufacturer instructions. Membranes were reacted using
different primary antibodies. The GPNMB/OA protein was
detected using the anti-GPNMB/OA antibody described above
(1 mg/ml ﬁnal concentration). The anti-GPNMB/OA antibody from
R&D System (AF2550) and the monoclonal anti-GPNMB/OA anti-
body (clone 1A8, Abnova) raised against human GPNMB/OA were
also preliminary tested. Primary antibodies anti-MMP-2 and anti-
MMP-9 both raised in mouse (1 mg/ml ﬁnal dilution) were
purchased from Millipore (Billerica, MA, USA). Lysates from
untreated, si-scrambled- and si-GPNMB/OA-treated DU145 and
PC3 cells were analyzed for the extracellular signal-regulated
kinases 1 and 2 (Erk1/2) phosphorylation and total Erk1/2, both
antibodies raised in mouse (0.4 mg/ml ﬁnal dilution; Santa CruzBiotechnologies, Heidelberg, Germany). The secondary antibody
raised in sheep (R&D Systems) (0.1 mg/ml ﬁnal concentration) was
applied for 1-h incubation at rt. A mouse polyclonal antibody
directed against the N-terminal region of human α-tubulin (Sigma
Aldrich Italia) was applied to cell extracts, to exclude that
difference in the band intensity of the corresponding proteins
could be due to errors in protein dosage or sample loading. The
speciﬁc signal was visualized by the ECL-PLUS system (Amersham
Italy, Milano, Italy). Densitometric analysis of the immunoblots
was performed using the GelPro-Analyzer version 6.0 (MediaCy-
bernetics, Bethesda, MD, USA).
In vitro invasion assay
The invasive potential of DU145 and PC3 cell lines was analyzed
as previously described [9]. Brieﬂy, untreated, si-scrambled and
si-GPNMB/OA-treated cells (105 cells/well) were resuspended in
DMEM–0.1% BSA medium and seeded in the inner side of
transwells (BD Biocot Matrigel Invasion Chamber, BD, Bedford,
MA, USA). After a 24-h incubation, cells in the inner chamber
were removed with a cotton swab. Cells attached to the bottom
side of the membrane were ﬁxed with methanol, stained with
toluidine blue, and counted.
Cell proliferation assay
Cell proliferation rate was evaluated as previously described
[10,11]. Brieﬂy, untreated, si-scrambled and si-GPNMB/OA-treated
DU145 and PC3 cells (5105 cells/well) were plated in culture
dishes. Twenty-four hours later, cells were washed and detached
with trypsin–EDTA. Cell suspensions containing 0.25% trypan blue
were dropped in a hemocytometer chamber and the viable cells
were blind counted under a phase contrast microscope by two
different operators. Results are the mean7SE of six different
dishes for each cell culture.
Double acridine orange/ethidium bromide (AO/EtBr)
staining
A double staining with AO and EtBr was performed to visualize
and quantify the number of viable, apoptotic and necrotic cells
[28]. Brieﬂy, untreated and si-scrambled- or si-GPNMB/OA-trea-
ted DU145 and PC3 cells (5105 cells/well) were centrifuged for
5 min at 700g and resuspended in PBS. The dye mixture (100 μg/
ml AO and 100 mg/ml EtBr) was added to cell suspension (1:10
ﬁnal dilution) and immediately examined by a Zeiss LSM 510
META confocal laser-scanning microscope, with 10 objective
(Carl Zeiss AG, Germany). Several ﬁelds, randomly chosen, were
digitalized and about 1000 nuclei for each sample were counted
and scored.
Gelatin zymography
MMP-2 and MMP-9 activity was measured in the conditioned
media of untreated and si-RNA treated DU145 and PC3 cells.
Conditioned media were resuspended in PBS, and equal amounts
of proteins (75 mg) were electrophoresed under non-reducing
conditions into 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gels polymerized with 0.1% gelatin. Gels were
washed twice in 2.5% Triton X-100 for 30 min at rt to remove SDS
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Tris–HCl and 10 mM CaCl2 at pH 8.0. Gels were stained with 0.5%
Coomassie Brilliant Blue in 50% methanol and 10% glacial acetic
acid for 30 min and destained with 50% methanol and 10% acetic
acid. Translucent bands were quantiﬁed by densitometry using G:
BoxChemiXT Imaging System (Syngene, UK).
Statistical analysis
Data analysis and graphics were obtained using GraphPad Prism 4
software. (GraphPad Software, La Jolla, CA). The statistical analysis
was made using the one-way ANOVA, with a post-hoc test
(Bonferroni's test) for multiple comparisons, considering po0.05
as threshold for signiﬁcant difference. Data are expressed as
mean7SE of at least three experiments run in triplicate, unless
otherwise speciﬁed.Results
Effect of NGF on GPNMB/OA expression in DU145 and PC3
cells
Microarray technology, employed in human metastatic DU145
cells to identify genes regulated by the differentiating treatment
with NGF [9,10], led to the identiﬁcation of cluster of genesFig. 1 – GPNMB/OA expression is reduced in DU145 (A) and PC3 (B) c
cells (b and d) were washed, ﬁxed in 95% ethanol for 10 min and 50
OA monoclonal antibody directed against the aa 22-486 sequence
Alexa Fluor488 anti-mouse secondary antibody was applied. Covers
staining was detected using the IX51 inverted ﬂuorescence micros
omitted (not shown). Magniﬁcation: 400 . The picture is represen
superimposable results.involved in various aspect of cellular physiology and pathology,
including invasion and metastasis [11]. Among these genes, a
signiﬁcant down-regulation of GPNMB/OA was observed
(untreated DU145 value: 180; NGF-treated DU145: 33.4, 5.4
fold change, po0.00002) suggesting an important role of this
glycoprotein in the mechanism underlying cancer progression.
DU145 and PC3 cells were then treated with NGF and analyzed for
GPNMB/OA mRNA and protein expression. Results obtained
demonstrated that in DU145 cells, mRNA encoding GPNMB/OA,
was signiﬁcantly reduced by NGF of 7.2 fold (70.4) as well as in
PC3 cells, where NGF treatment down regulated GPNMB/OA gene
by 7.3 fold (70.9) compared to untreated cells. Commercially
available human primary prostate epithelial cells were used as
internal control, to evaluate the GPNMB/OA expression in normal
tissue: Q-RT-PCR experiments with 5-fold serial dilutions of cDNA
revealed a low detectable level of GPNMB/OA mRNA transcript
only at the two highest cDNA concentrations (respectively 4 ng/μl:
ΔCt¼15.870.13; 0.8 ng/μl: ΔCt¼15.770.11), while lower cDNA
concentrations have not given rise to PCR products.
GPNMB/OA protein expression was evaluated by immunocyto-
chemistry, using an anti-human GPNMB/OA antibody. As shown
in Fig. 1, a positive immunoreactivity signal for GPNMB/OA was
observed in both untreated cell lines, mostly localized at the
membrane level and in the pericytoplasmic compartment (panels
A and C), while NGF-treatment strongly reduced GPNMB/OA
protein expression in both DU145 and PC3 cells (panels B andell lines by NGF treatment. Untreated (a and c) and NGF-treated
% ethanol for 5 min and incubated with a primary anti-GPNMB/
of the human protein (0.4 lg/ml). After extensive washes, the
lips were mounted using the FluorPreserve™ Reagent and cell
cope. No signal was detected when the primary antibody was
tative of at least three independent experiments, with
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omitted (not shown).GPNMB silencing in DU145 and PC3 cells
To gain insight into the role of GPNMB/OA in PCa cell lines, the
siRNA approach was used. Preliminary experiments were con-
ducted using a pool of four siRNA duplexes targeting different
regions of the human GPNMB/OA gene (si-GPNMB/OA) and of
non-targeting scrambled control siRNA duplex (si-scrambled),
tested at different concentrations (10–100 nM) for different times
(72–120 h), to ﬁnd out the most selective and efﬁcient treatment
in silencing GPNMB/OA in both cell lines (data not shown).
Transfection with siRNA for 120 h, at ﬁnal concentrations of
50 nM and 10 nM, efﬁciently down-regulated GPNMB/OA proteinTable 1 – GPNMB/OA siRNA treatment strongly reduced the level
ΔCt
DU145 CELLS
Untreated 11.770.1
si-Scrambled-treated 11.570.1
si-GPNMB/OA-treated 14.970.1
PC3 CELLS
Untreated 17.070.1
si-Scrambled-treated 17.170.1
si-GPNMB/OA-treated 19.870.5
Cells were exposed for 120 h to si-GPNMB/OA or to si-scrambled, using the ON
One microgram of the total RNA extracted was retrotranscribed and used
experiments run in triplicate.
n po0.01 vs. untreated DU145 cells.
nn po0.05 vs. untreated PC3 cells.
Fig. 2 – Analysis of protein expression in GPNMB/OA silenced DU4
Untreated, si-scrambled-treated and si-GPNMB/OA-treated cells an
membranes were reacted with goat polyclonal afﬁnity-puriﬁed an
protein. The human α-tubulin was used as internal control. The sp
bands migrating as a doublet between 60 and 120 kDa were detecte
[39,40]. The GPNMB/OA extracellular fragment, produced by plasma
was detected in the conditioned medium of untreated and siRNA-
three independent experiment, with superimposable results.in DU145 and PC3 cells, respectively. Therefore these conditions
were used for subsequent experiments.
In particular, transfection of DU145 cells with si-GPNMB/OA
(50 nM) for 5 days, signiﬁcantly reduced GPNMB/OA mRNA levels,
measured by Q-RT-PCR (89%; po0.01, Table 1). The speciﬁcity of
this effect was validated by transfecting cells with the si-scrambled
(50 nM; 5 days), that was unable to affect GPNMB/OA mRNA
expression (þ12%). GPNMB/OA expression was also detected by
western blot in DU145 cell lysates, multiple bands migrating
between 60 and 120 kDa were detected (Fig. 2A), representing the
different glycosylation forms of the protein [29,30]. Different pri-
mary antibodies raised against human GPNMB/OA were also tested,
recognizing a similar pattern of bands, thus suggesting that several
isoforms of GPNMB/OA are expressed in DU145 cells (data not
shown). As shown in Fig. 2A, while no differences were detected
between control and si-scrambled-treated cells, the expression ofof GPNMB/OA mRNA in DU145 and PC3 cell lines.
ΔΔCt % vs. untreated cells
– –
0.2 þ12
þ3.2 89n
– –
þ0.1 10
þ2.8 86nn
-TARGETplus SMARTpool system, as described in Materials and methods.
for the Q-RT-PCR. Data are expressed as mean7SE of at least three
5 (A) and PC3 (B) cellular extracts and conditioned media.
d conditioned media were processed as described. The
tibody raised against the aa 23-486 of the human GPNMB/OA
eciﬁc signal was visualized by the ECL-PLUS system. Multiple
d, representing the different glycosylation forms of the protein
membrane cleavage and accumulated in the cell culture media
treated cells, as described. The blot is representative of at least
Table 2 – In vitro effects of GPNMB/OA silencing on DU145 cell line.
Cell proliferation Cells/ﬁeld (103) % vs. untreated
Untreated 268.3730.7 –
si-Scrambled-treated 250.6720.5 6.6
si-GPNMB/OA-treated 181.2723.8 32.5n
In vitro invasiveness Cells/ﬁeld (103) %
Untreated 9.570.6 –
si-Scrambled-treated 9.070.8 5.3
si-GPNMB/OA-treated 3.570.5 63.1nn
DU145 cells were plated and treated with si-scrambled or si-GPNMB/OA using the ON-TARGETplus SMARTpool system, as described in Materials and
methods.
Cell proliferation: untreated cells, si-scrambled- and si-GPNMB/OA-treated DU145 cells were then detached, washed in PBS and counted. For direct
counting with the hemocytometer, ﬁve ﬁelds for each treatment condition were counted, and counts were made in at least three separate experiments.
Data are the mean7SE from three different experiments run in quadruplicate.
In vitro invasiveness: untreated cells, si-scrambled- and si-GPNMB/OA-treated DU145 cells were detached and plated on Matrigel-coated ﬁlters. After a
24-h incubation, cells attached to the lower face of the ﬁlter were ﬁxed, stained, and counted. Results are the mean7SE from three different experiments
run in triplicate.
n po0.01 vs. untreated DU145 cells.
nn po0.001 vs. untreated DU145 cells.
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DU145 cells (% vs. untreated cells: 60 kDa: 7274.8%; po0.05;
75 kDa: 7575.3%; po0.05; 100 kDa: 7771.9%; po0.001;
120 kDa: 86.471,1%; po0.05). Moreover, the GPNMB/OA extra-
cellular fragment, produced by plasma membrane cleavage and
accumulated in the cell culture media [31], was measured in the
conditioned medium of untreated and siRNA-treated DU145 cells.
Fig. 2A shows a band of approximately 100 kDa in the media of
untreated cells that was unaffected by treatment with si-scrambled
(92.671.7%), while was signiﬁcantly reduced in si-GPNBM/OA-
treated (% vs. untreated cells: 66.974.1%; po 0.01).
PC3 transfection with 10 nM si-GPNMB/OA for 120 h speciﬁcally
and signiﬁcantly reduced both mRNA and protein expression, as
shown in Table 1 and Fig. 2B. Evaluation of GPNMB/OA expression
by western blot, revealed the presence in PC3 cell lysates of
three major bands corresponding to about 100 kDa, 60 kDa and
46 kDa (Fig. 2B). As shown for DU145 cells, a similar pattern of
GPNMB/OA isoforms were detected by using different anti-
GPNMB/OA primary antibodies (data not shown). Decreased
GPNMB/OA expression was speciﬁcally revealed in si-GPNMB/
OA-treated PC3 cells (% vs. untreated cells: 46 kDa: 52.37
3.9%; po0.001; 60 kDa: 69.472.8%; po0.05; 100 kDa:
5473.2%; po0.05) (Fig. 2B), while si-scrambled did not affect
GPNMB/OA levels (Fig. 2B), indicating the speciﬁcity of protein
silencing. The GPNMB/OA extracellular fragment, accumulated in
the supernatant of control and siRNA-treated PC3 cells was also
measured by western blot, as described above. The 70 kDa band
detected in the culture media of untreated cells (Fig. 2B) was
signiﬁcantly reduced in si-GPNBM/OA-treated cells (% vs.
untreated cells: 18.571.4%; po0.001), but unchanged by si-
scrambled treatment.
Role of GPNMB/OA in DU145 cells
si-GPNMB/OA-treated DU145 cells were then tested for functional
activity. The effect of GPNMB/OA knockdown on cell proliferation
was ﬁrst examined. For cell counting, cells were detached andcounted using a hemocytometer [10,11]. As shown in Table 2,
silencing of GPNMB/OA resulted in a reduction of DU145 cell
proliferation rate of about 32.5% compared to control and si-
scrambled-treated cells. The double staining with AO/EtBr was
performed on untreated and si-RNA-treated DU145 cells, reveal-
ing that silencing GPNMB/OA deeply increased the number of
apoptotic cells (þ6973.1%; po0.001). By contrast, apoptotic cells
were almost entirely absent in GPNMB/OA expressing cells
(Fig. 3). These data thus suggest that in DU145 cells, impairment
of apoptosis could be the main mechanism involved in cancer cell
growth regulation induced by GPNMB/OA.
By using the Matrigel invasion assay, the effect of inhibiting
GPNMB/OA expression in DU145 cells was also tested on their
in vitro invasive potential, a key event leading to metastasis formation.
Table 2 reports that silencing of GPNMB/OA substantially reduced the
migration capability through Matrigel of DU145 cells (63.171.6%;
po0.001), in contrast to control and si-scrambled DU145 cells.
Role of GPNMB/OA in PC3 cells
To establish whether the role of GPNMB/OAwas peculiar for DU145
cells or it could represent a biomarker of PCa progression, the effect
of GPNMB/OA silencing on cell proliferation and invasion capability
was studied in PC3 cells as well. Results reported in Table 3
indicated that GPNMB/OA-silenced PC3 cells inhibited their cell
proliferation rate, although the extent did not reach the statistical
signiﬁcance (16% vs. controls). Interestingly, the GPNMB/OA
knockdown substantially reduced the migration capability through
Matrigel of PC3 cells (61.474.11%; po0.001; Table 3) compared
to untreated and si-scrambled-treated cells (4.6% of reduction).
GPNMB/OA induces up-regulation of metalloproteinase
2 and 9 (MMP-2 and MMP-9) in DU145 and PC3 cells
To investigate the molecular mechanisms underlying GPNMB/OA
effects on PCa human cell lines invasiveness, DU145 and PC3 cells
were analyzed for the expression and function of MMP-2 and
Fig. 3 – Effect of GPNMB/OA silencing on apoptotic cell death in DU145 cells. Untreated (A), si-scrambled (B) and si-GPNMB/OA-
treated DU145 cells (C) were stained using AO/EtBr, as described in the Materials and methods. Viable cells (green), necrotic cells
(red) and apoptotic cell (yellow) were visualized and quantiﬁed by using a confocal laser-scanning microscope. Magniﬁcation:
100 . The blot is representative of at least three independent experiment, with superimposable results.
Table 3 – In vitro effects of GPNMB/OA silencing on PC3 cell line.
Cell proliferation Cells/ﬁeld (103) % vs. untreated
Untreated 251.0775.5 –
si-Scrambled-treated 267.2786.0 þ6
si-GPNMB/OA-treated 210.8786.3 16
In vitro invasiveness Cells/ﬁeld (103) %
Untreated 35.571.1 –
si-Scrambled-treated 34.071.5 4.6
si-GPNMB/OA-treated 13.973.2 61.4n
PC3 cells were plated and treated with si-scrambled or si-GPNMB/OA using the ON-TARGETplus SMARTpool system (Invitrogen), as described in
Materials and methods.
Cell proliferation: untreated cells, si-scrambled- and si-GPNMB/OA-treated PC3 cells were then detached, washed in PBS and counted. For direct
counting with the hemocytometer, ﬁve ﬁelds for each treatment condition were counted, and counts were made in at least three separate experiments.
Data are the mean7SE from three different experiments run in quadruplicate.
In vitro invasiveness: untreated cells, si-scrambled- and si-GPNMB/OA-treated PC3 cells were detached and plated on a Matrigel-coated ﬁlters. After a
24-h incubation, cells attached to the lower face of the ﬁlter were ﬁxed, stained, and counted. Results are the mean7SE from three different experiments
run in triplicate.
n po0.001 vs. untreated PC3 cells.
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reported in Fig. 4 show that silencing GPNMB/OA protein deeply
affected MMP-2 and MMP-9 expression in both cell lines, being
reduced by 3870.5% (po0.01) and 5971.1% (po0.001), respec-
tively, in DU145 cells and by 3471.1% (po0.01) and 5670.7%
(po0.01), respectively, in PC3 cells, compared to the relative
untreated cells. By contrast, in these cell lines, the expression
levels of both the proteinases were unchanged following si-
scrambled-treatment (Fig. 4). In addition, decreased levels of
MMP-2 and MMP-9 were exclusively detected in the culture
media of si-GNPMB/OA-treated DU145 cells (5573.6%,
po0.01, and 7171.05%, po005, respectively) as well as PC3
cells (7270.7%, po0.05; 6472.7%; po0.01, respectively),
compared to the levels detected in the media of both control
and si-scrambled-treated cells, thus suggesting that GPNMB/OA
speciﬁcally regulates the production and the release of these
speciﬁc MMPs.
Gelatin zymography assay was then performed on the condi-
tioned media, to evaluate MMP-2 and MMP-9 activity (Fig. 5).A signiﬁcant decrease of MMP-2 and MMP-9 functionality char-
acterized the conditioned medium of both si-GPNMB/OA-treated
DU145 cells (6372%, po0.05 and 4972.3%, po0.001, respec-
tively) and si-GPNMB/OA-treated PC3 cells (7271.7%, po0.05;
6773.7%, po0.001, respectively). By contrast, MMPs activity
was preserved in untreated and si-scrambled-treated DU145 and
PC3 cell lines (Fig. 5).
The mRNA expression levels of tissue inhibitors of matrix
metalloproteinases 1 and 2 (TIMP1 and TIMP2), and the endo-
genous molecules contrasting the activity of MMP-2 and MMP-9
[33] were also evaluated. We found that in both the cell lines,
GPNMB/OA silencing did not affect TIMP 1 and TIMP 2 mRNA
(data not shown) suggesting that GPNMB/OA-mediated regulation
of invasiveness seems not to involve TIMPs regulation.
Finally, since evidence of MMPs regulation by the extracellular
signal-regulated kinases 1 and 2 (Erk1/2) pathway has been
described in different invasive tumors [34,35], phosphorylation
of Erk1/2 was evaluated in the lysates from both untreated
and si-scrambled- or si-GPNMB/OA-treated DU145 and PC3 cells.
Fig. 5 – Effect of GPNMB/OA silencing on MMP-2 and MMP-9
activities. Conditioned media collected from untreated, si-
scrambled-treated and si-GPNMB/OA-treated DU145 and PC3
cells (75 lg) were used for gelatin zymography assay. The gels
were scanned and the images used for the densitometric
analyses. The active forms of MMP-2 (E68 kDa) and MMP-9
(E84 kDa) were analyzed. Images were acquired and analyzed
by using G: BoxChemiXT Imaging System (Syngene, UK). The
experiment was repeated at least three times with
superimposable results.
Fig. 4 – Effect of GPNMB/OA silencing on metalloproteinase
MMP-2 and MMP-9 expression in DU145 and PC3 cells.
Untreated, si-scrambled-treated and si-GPNMB/OA-treated
DU145 and PC3 cells and conditioned media were processed as
described. The membranes were reacted with goat polyclonal
afﬁnity-puriﬁed antibodies raised against human MMP-2 and
MMP-9. In the cell lysates, MMP-2 and MMP-9 were detected as
a bands of about 72 kDa and 92 kDa, respectively. The human
α-tubulin was used as internal control. In the conditioned
media, the active forms of MMP-2 and MMP-9 were detected as
a bands of about 68 kDa and 84 kDa, respectively. The speciﬁc
signal was visualized by the ECL-PLUS system. The blot is
representative of three independent experiments, with
superimposable results.
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were detected in both control and si-scrambled DU145 and PC3
cells, that were not modify by GPNMB/OA silencing (data not
shown).Discussion
The glycoprotein GPNMB/OA, expressed in a wide array of normal
tissue, is involved in various pathological conditions, including
cancer. Association of GPNMB/OA expression and cancer, indeed,
has been revealed in liver cancer, squamous cell lung carcinoma
and soft tissue tumors [16,36,37] as well as cutaneous [15,38] and
uveal melanoma [14]. Moreover, GPNMB has been found in manyBC cell lines and tumors [19–21] where a strong correlation
between GPNMB/OA overexpression and aggressive phenotype
has been clearly deﬁned [19,20]. Accordingly, GPNMB/OA has
been also detected in a signiﬁcant portion of high-grade glioma
tumors, but not in normal tissue, and its expression is a useful and
powerful prognostic marker of poor survival [18].
Here, we demonstrated that GPNMB/OA was expressed in
DU145 and PC3 cell lines, derived from human metastatic PCa.
GPNMB/OA expression correlated with their malignant pheno-
type: both gene expression and immunistochemical analyses
showed that GPNMB/OA expression was signiﬁcantly decreased
by NGF treatment, an experimental model of PCa cell lines
differentiation previously characterized in our laboratories [9–11]
thus suggesting that GPNMB/OA may be involved in the molecular
mechanisms promoting the progression of PCa. The intracellular
events underlying NGF-induced modulation of GPNBM/OA expres-
sion is still not yet clariﬁed. For several cancer cell lines, the
dysregulation of the NGF and NGF receptor pathway has been
associated with the progression toward a more maligned pheno-
type [9,39–41]. In particular, the key point seems to be linked to
the p75NGFR expression, as a strong correlation between cancer
progression and decreased levels of p75NGFR has been observed
[10,40,42,43].
On this line, in the prostate p75NGFR, progressively lost during
carcinogenesis [44,45] has been proposed as a tumor suppressor
and anti-metastatic gene [45–47], involved in cell differentiation
[48], cell growth inhibition and apoptosis [49,50]. p75NGFR-
mediated signals involve the activation of the nuclear factor-kB
(NF-κB) [50–52], a transcriptional factor able to either stimulate
or inhibit gene synthesis depending on several mechanisms, such
as the subunit composition of NF-κB complexes [53–55]. In line
with these observations, analyses of the human GPNMB/OA
promoter sequence ( “Promo” Software, version 8.3 of TRANSFAC)
[56,57] showed the existence of at least one putative NF-κB-
responsive element, indicating that GPNMB/OA might be a NGF-
mediated NF-κB-regulated gene. However, whether these mole-
cular events are operating in DU145 and PC3 cells is now under
investigation.
To clarify the role of GPNMB/OA in the PCa, we chose the mRNA
silencing approach (siRNA) to investigate the role of GPNMB/OA in
DU145 and PC3 cell lines. The siRNA approach led us to observe
that, both the transmembrane protein as well as the extracellular
peptide were strongly reduced. The transmembrane and secreted
GPNBM/OA were detected in different molecular masses in DU145
and PC3 cells; the observed discrepancies about the GPNMB/OA
molecular weight between the two cell lines, and more generally
among the several cell types expressing GPNMB/OA [58], could be
due to the different patterns of protein glycosylation processes
[59]; GPNMB/OA, indeed, is heavily glycosylated by N-linked and
O-linked glycans [29], having potential 11 N-linked [30] and 19 O-
linked glycosylation sites [29], conferring to the protein peculiar
properties in processing, folding and trafﬁcking. In line with these
observations, in DU145 cells numerous cell-associated GPNMB/OA
isoforms were detected, ranging from 60 to 100 kDa, that were
speciﬁcally silenced by siRNA treatment. Moreover, DU145 cells
released a unique highly glysosylated/mature isoform form of
100 kDa [29]. By contrast, PC3 cells expressed several GPNMB/OA
isoforms, highly reduced by siRNA silencing, detected both in cell
lysates, with molecular masses from 50 to 100 kDa, and in cell
supernatants, as an individual band of 70 kDa, suggesting an
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with the observation that changes in the expression and activity
of sialtranferases, responsible for the addition of sialic acid to
glycans, have been associated with malignant potential in several
tumors [60,61], our data may suggest that defective activities of
these enzymes may occur in PC3 cells. Further experiments will
elucidate the biological activity of both the released GPNMB/OA
species detected in the conditioned media of DU145 and PC3 cells.
Silencing GPNMB/OA robustly affected the ability of DU145 and
PC3 cells to transmigrate through a synthetic membrane, estab-
lishing a correlation between GPNMB/OA expression and the
tendency of invasiveness to adjacent normal tissue and of migra-
tion to distant organs. Among the multiple steps of PCa progres-
sion, the ability to break down the extracellular matrix represents
a critical event for tumor invasion and metastasis that activates
proteinases such as the matrix metalloproteinase (MMPs) [32], as
well as their speciﬁc modulators, the tissue inhibitors of MMPs
(TIMPs) [33]. Several evidences suggesting the crucial role of
MMPs for PCa metastasis mechanisms have been collected: over-
production of MMP-2 and MMP-9 has been associated with more
aggressive PCa phenotypes [25,62], high plasma and urine levels
of MMPs have been measured in patient with PCa [62,63]; loss of
TIMPs activity [64] or imbalance between MMPs and TIMPs, has
been preferentially detected in primary PCa tissue, but not in
normal prostate epithelium [65,66]. In line with these observa-
tions, altered production of MMP-2/-9 and/or MMPs/TIMPs
imbalance has been described in both DU145 and PC3 cells
[67,68]. Previous works have shown that in a non-invasive
genetically deﬁned human glioma cell line, the ectopic expression
of GPNMB/OA signiﬁcantly increased invasion capability mainly
by increasing MMPs production [17] and the sustained MMP-3
expression induced by GPNMB/OA enhanced in vivo invasiveness
of a bone metastatic BC cells [19]. On this line, we found that
GPNMB/OA silencing induced a signiﬁcant down-regulation of
MMP-2 and MMP-9 expression level and activity, detected in both
DU145 and PC3 lysates and conditioned medium. By contrast,
mRNA levels of TIMP-1 and TIMP-2 were not affected by this
glycoprotein suggesting that the unique regulation of both the
MMPs by GPNMB/OA may be crucial components contributing to
the acquisition of the highly invasive phenotype that charac-
terizes both DU145 and PC3 metastatic cell lines. In line with our
results, pharmacological or molecular strategies aimed to inhibit
MMPs activities in both DU145 and PC3 cells, including drugs or
mRNA silencing techniques, have been found to strongly affect
PCa cells invasiveness and migration [24,69,70]. Among the
numerous MMPs, enhanced MMP-2 and MMP-9 activity has been
found to contribute to tumor invasion and metastasis in human
PCa patients [25,62,63]. However, other MMPs, such as MMP-1,
MMP-11 or MMP-13 have been shown to have an impact on
diagnosis and survival of PCa patients [62,71–73] suggesting an
extreme variability in the abnormalities of MMPs system likely
caused by the biological heterogeneity of PCa tumors. By contrast,
TIMPs expression and correlation with tumor progression appear
to be more intricate since these multifunctional proteins exhibit
both tumor suppressor and tumor promoting effects [74,75]. The
precise mechanism of GPNMB/OA modulation of MMP-2 and
MMP-9 synthesis and release is not well understood. However,
in NIH-3T3 ﬁbroblast cells it has been demonstrated that a
recombinant extracellular fragment of GPNMB/OA had the ability
to induce up-regulation of another member of the MMP family,namely MMP-3, via Erk1/2 pathway activation [31]. In these
experiments, MMP-3 modulation by the extracellular domain
GPNMB/OA likely occurred through the interaction with a hepar-
ine sulfate proteoglycan-type receptor for osteoactivin, not iden-
tiﬁed yet [31]. In the present study, silencing GPNMB/OA did not
alter the amount of Erk1/2 phosphorylation in both cell lines
suggesting that other intracellular events may be involved in
GPNMB/OA-induced activation of MMPs. Further experiments will
elucidate whether these mechanisms really occur in PCa cell lines.
GPNMB/OA affected also cell proliferation, although with a
lesser extent compared to invasiveness, thus suggesting its
involvement in this phenomenon. In DU145 cells, indeed,
GPNMB/OA knock-down induced a slight reduction in the pro-
liferation rate, that was mainly due to an increase of apoptotic cell
death. Since balance between cell proliferation and cell death or
apoptosis deeply affects tumor growth, our ﬁndings indicate that
DU145 cell proliferation induced by GPNMB/OA may be mainly
related to its anti-apoptotic properties [21,76]. Although several
in vitro studies carried out on genetically deﬁned glioma cells
clearly excluded any impact of GPNMB/OA on cell proliferation or
apoptosis [17], recently in vivo studies revealed that GPNMB/OA
overexpression in BC cells enhances primary tumor growth both
indirectly, by up-regulating Vascular Endothelial Growth Factor
(VEGF), and by the direct recruitment of endothelial cells, thus
promoting angiogenesis: this effect was speciﬁcally induced by
the secreted form of GPNMB/OA [21]. In line with our data,
immunohistochemical analysis of GPNMB/OA-expressing tumors
revealed, in addition to increased vascular density, a decreased
number of apoptotic cells, suggesting a speciﬁc and more direct
role of this glycoprotein in the control of apoptotic mechanisms
[21,76]. Our results indicate that silencing GPNMB/OA in PC3 cells,
however, had a slight impact on the cell proliferation rate. This
result may ﬁnd its rational in different metastatic origins of
DU145 and PC3 cell lines (brain and bone, respectively), thus is
reasonable that distinctive molecular modiﬁcations may have
occurred, that strongly inﬂuence GPNMB/OA biological activities.
Recent data from Tsui et al. [23], however, suggested an opposite
role of GPNMB/OA in PCa cells: while this glycoprotein was
detected in LNCaP cell lines, they found extremely low levels in
DU145 and PC3 cell lines. This discrepancy may have a technical
explanation, due to different cell culture conditions and/or
experimental approaches. Moreover, they found that overexpres-
sing GPNMB/OA in PC3 cell lines had the ability to reduce
proliferation rate and tumorigenesis, thus exerting an anti-
tumorigenic activity: this discrepancy can ﬁnd its rationale in
the distinct study design, as the transfection-induced expression
of GPNMB/OA may allow protein overexpression, an usual con-
sequence of this experimental technique, and may explain the
conﬂicting results.
In conclusion, GPNMB/OA is emerging as an important protein
that plays a role in the progression of a number of human tumors,
including PCa. Several GPNMB/OA-dependent mechanisms,
including the modulation of MMPs activity here described, the
promotion of tumor growth and angiogenesis [21], as well as the
capability to inhibit the tumor-reactive T-cell, leading to tumor
escape from immunological destruction [77], might contribute to
prostate cancer tumor progression. Although studies on human
prostate and PCa tissues are needed, this may become a new
biomarker, which could help clinicians to take the most appro-
priate and/or more aggressive treatment decisions, in the light
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adjacent tissue and to promote metastasis. Furthermore, GPNMB/
OA may represent an ideal and therefore promising target for an
antibody-based therapy, due, in particular, to the prevalent cell
surface expression on cancer cells, in contrast to the predomi-
nantly intracellular expression in normal cells [18]. On this line,
engineered GPNMB/OA-speciﬁc high-afﬁnity single chain anti-
body fragment, known as CR0011-vcMMAE or glembatumumab
vedotin, has been linked to the auristatin E cytotoxin, showing a
potent anti-tumor activity both in preclinical studies [15,78,79],
and in phases I/II clinical trials for patients with advanced
melanoma and BC [14,80,81].Conﬂicts of interest
AB received lecture fees from Janssen, Astellas Pharma and Xanoﬁ,
PFS was a consultant for Roche, DZ was a consultant from Ipsen
and received lecture fees from GlaxoSmithKline, and SS received
lecture fees from AstraZeneca and GlaxoSmithKine. These colla-
borations are not related to the topic of the present manuscript.
CF, SB, FB, MF, SAB, CS, CM, and MM have nothing to disclose.Acknowledgment
This project was supported by the Fondazione Guido Berlucchi
per la Ricerca sul cancro onlus (Borgonato, Bs, Italy).
r e f e r e n c e s
[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer
statistics, CA: Cancer J. Clin. 59 (2009) 225–249.
[2] V. Mouraviev, J.M. Mayes, T.J. Polascik, Pathologic basis of focal
therapy for early-stage prostate cancer, Nat. Rev. Urol. 6 (2009)
205–215.
[3] P.S. Nelson, Molecular states underlying androgen receptor
activation: a framework for therapeutics targeting androgen
signaling in prostate cancer, J. Clin. Oncol. 30 (2012) 644–646.
[4] A. Zivi, C. Massard, J. De-Bono, Changing therapeutic paradigms
in castrate-resistant prostate cancer, Clin. Genitourin.Cancer 8
(2010) 17–22.
[5] L.A. Garraway, W.R. Sellers, Lineage dependency and lineage-
survival oncogenes in human cancer, Nat. Rev. Cancer 6 (2006)
593–602.
[6] D. Djakiew, Dysregulated expression of growth factors and their
receptors in the development of prostate cancer, Prostate 42
(2000) 150–160.
[7] X. Montano, M.B. Djamgoz, Epidermal growth factor, neurotro-
phins and the metastatic cascade in prostate cancer, FEBS Lett.
571 (2004) 1–8.
[8] N. Arrighi, S. Bodei, D. Zani, C. Simeone, S.C. Cunico, C. Missale,
P.F. Spano, S. Sigala, Nerve growth factor signaling in prostate
health and disease, Growth Factors 28 (2010) 191–201.
[9] S. Sigala, I. Faraoni, D. Botticini, M. Paez-Pereda, C. Missale,
E. Bonmassar, P.F. Spano, Suppression of telomerase, reexpression
of KAI1, and abrogation of tumorigenicity by nerve growth factor
in prostate cancer cell lines, Clin. Cancer Res. 5 (1999) 1211–1218.
[10] S. Sigala, N. Tognazzi, M.C. Rizzetti, I. Faraoni, C. Missale,
E. Bonmassar, P.F. Spano, Nerve growth factor induces the re-
expression of functional androgen receptors and p75 (NGFR) in
the androgen-insensitive prostate cancer cell line DU145, Eur.
J. Endocrinol. 147 (2002) 407–415.[11] S. Sigala, S. Bodei, C. Missale, D. Zani, C. Simeone, S.C. Cunico,
P.F. Spano, Gene expression proﬁle of prostate cancer cell lines:
effect of nerve growth factor treatment, Mol. Cell. Endocrinol.
284 (2008) 11–20.
[12] F.F. Safadi, J. Xu, S.L. Smock, M.C. Rico, T.A. Owen, S.N. Popoff,
Cloning and characterization of osteoactivin, a novel cDNA
expressed in osteoblasts, J. Cell. Biochem. 84 (2001) 12–26.
[13] M. Singh, F. Del Carpio-Cano, J.Y. Belcher, K. Crawford, N. Frara,
T.A. Owen, S.N. Popoff, F.F. Safadi, Functional roles of osteoactivin
in normal and disease processes, Crit. Rev. Eukaryot. Gene Expr.
20 (2010) 341–357.
[14] M.D. Williams, B. Esmaeli, A. Soheili, R. Simantov, D.S. Gombos, A.
Y. Bedikian, P. Hwu, GPNMB expression in uveal melanoma: a
potential for targeted therapy, Melanoma Res. 20 (2010)
184–190.
[15] K.F. Tse, M. Jeffers, V.A. Pollack, D.A. McCabe, M.L. Shadish, N.V.
Khramtsov, C.S. Hackett, S.G. Shenoy, B. Kuang, F.L. Boldog, J.R.
MacDougall, L. Rastelli, J. Herrmann, M. Gallo, G. Gazit-Bornstein,
P.D. Senter, D.L. Meyer, H.S. Lichenstein, W.J. LaRochelle, CR011, a
fully human monoclonal antibody–auristatin E conjugate, for the
treatment of melanoma, Clin. Cancer Res. 12 (2006) 1373–1382.
[16] M. Onaga, A. Ido, S. Hasuike, H. Uto, A. Moriuchi, K. Nagata,
T. Hori, K. Hayash, H. Tsubouchi, Osteoactivin expressed during
cirrhosis development in rats fed a choline-deﬁcient, L-amino
acid-deﬁned diet, accelerates motility of hepatoma cells,
J. Hephatol. 39 (2003) 779–785.
[17] J.N. Rich, Q. Shi, M. Hjelmeland, T.J. Cummings, C.T. Kuan, D.D.
Bigner, C.M. Counter, X.F. Wang, Bone-related genes expressed in
advanced malignancies induce invasion and metastasis in a
genetically deﬁned human cancer model, J. Biol. Chem. 278
(2003) 15951–15957.
[18] C.T. Kuan, K. Wakiya, J.M. Dowell, J.E. Herndon 2nd, D.A. Reardon,
M.W. Graner, G.J. Riggins, C.J. Wikstrand, D.D. Bigner, Glycopro-
tein nonmetastatic melanoma protein B, a potential molecular
therapeutic target in patients with glioblastoma multiforme, Clin.
Cancer Res. 12 (2006) 1970–1982.
[19] A.A. Rose, F. Pepin, C. Russo, J.E. Abou Khalil, M. Hallett,
P.M. Siegel, Osteoactivin promotes breast cancer metastasis to
bone, Mol. Cancer Res. 5 (2007) 1001–1014.
[20] A.A. Rose, A.A. Grosset, Z. Dong, C. Russo, P.A. Macdonald,
N.R. Bertos, Y. St-Pierre, R. Simantov, M. Hallett, M. Park,
L. Gaboury, P.M. Siegel, Glycoprotein nonmetastatic B is an
independent prognostic indicator of recurrence and a novel
therapeutic target in breast cancer, Clin. Cancer Res. 16 (2010)
2147–2156.
[21] A.A. Rose, M.G. Annis, Z. Dong, F. Pepin, M. Hallett, M. Park, P.M.
Siegel, ADAM10 releases a soluble form of the OA/osteoactivin
extracellular domain with angiogenic properties, PLOS One 5
(2010) e12093.
[22] Y.B. Xiao, Z.G. Qiao, X.W. Zhang, Z.H. Liu, J. Xie, Y.C. Hao, W.D. Yu,
T. Xu, X.F. Wang, Expression of glycoprotein non-metastatic
melanoma protein B in prostate cancer and its signiﬁcance,
Beijing Da Xue Xue Bao 43 (2011) 496–499.
[23] K.H. Tsui, Y.L. Chang, T.H. Feng, P.L. Chang, H.H. Juang, Glyco-
protein transmembrane nmb: an androgen-downregulated gene
attenuates cell invasion and tumorigenesis in prostate carcinoma
cells, Prostate 72 (2012) 1431–1442.
[24] B.L. Lokeshwar, MMP inhibition in prostate cancer, Ann.
N. Y. Acad. Sci. 878 (1999) 271–289.
[25] J.A. Nemeth, R. Yousif, M. Herzog, M. Che, J. Upadhyay,
B. Shekarriz, S. Bhagat, C. Mullins, R. Fridman, M.L. Cher, Matrix
metalloproteinase activity, bone matrix turnover, and tumor cell
proliferation in prostate cancer bone metastasis, J. Nat. Cancer
Inst. 94 (2002) 17–25.
[26] S.T. Reis, J. Pontes-Junior, A.A. Antunes, J.M. de Sousa-Canavez,
M.F. Dall'Oglio, C.C. Passerotti, D.K. Abe, A. Crippa, J.A. da Cruz,
L.M. Timoszczuk, M. Srougi, K.R. Leite, MMP-9 overexpression
due to TIMP-1 and RECK underexpression is associated with
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 3 ( 2 0 1 4 ) 1 0 0 – 1 1 1110prognosis in prostate cancer, Int. J. Biol. Markers 26 (2011)
255–261.
[27] R. Aalinkeel, B.B. Nair, J.L. Reynolds, D.E. Sykes, S.D. Mahajan,
K.C. Chadha, S.A. Schwartz, Overexpression of MMP-9 contri-
butes to invasiveness of prostate cancer cell line LNCaP, Immu-
nol. Investig. 40 (2011) 447–464.
[28] E.V. Mironova, A.A. Evstratova, S.M. Antonov, A ﬂuorescence vital
assay for the recognition and quantiﬁcation of excitotoxic cell
death by necrosis and apoptosis using confocal microscopy on
neurons in culture, J. Neurosci. Methods 163 (2007) 1–8.
[29] S.M. Abdelmagid, M.F. Barbe, M.C. Rico, S. Salihoglu, I. Arango-
Hisijara, A.H. Selim, M.G. Anderson, T.A. Owen, S.N. Popoff, F.F.
Safadi, Osteoactivin, an anabolic factor that regulates osteoblast
differentiation and function, Exp. Cell Res. 314 (2008)
2334–2351.
[30] A.A. Selim, S.M. Abdelmagid, R.A. Kanaan, S.L. Smock, T.A. Owen,
S.N. Popoff, F.F. Safadi, Anti-osteoactivin antibody inhibits
osteoblast differentiation and function in vitro, Crit. Rev. Eukar-
yot. Gene Expr. 13 (2003) 265–275.
[31] H. Furochi, S. Tamura, M. Mameoka, C. Yamada, T. Ogawa, K.
Hirasaka, Y. Okumura, T. Imagawa, S. Oguri, K. Ishidoh, K. Kishi, S.
Higashiyama, T. Nikawa, Osteoactivin fragments produced by
ectodomain shedding induce MMP-3 expression via ERK path-
way in mouse NIH-3T3 ﬁbroblasts, FEBS Lett. 581 (2007)
5743–5750.
[32] J.L. Jones, R.A. Walker, Control of matrix metalloproteinase
activity in cancer, J. Pathol. 183 (1997) 377–379.
[33] G. Murphy, Tissue inhibitors of metalloproteinases, Genome Biol.
12 (2011) 233–240.
[34] C.T. Tan, C.Y. Chu, Y.C. Lu, C.C. Chang, B.R. Lin, H.H. Wu, H.L. Liu, S.
T. Cha, E. Prakash, J.Y. Ko, M.L. Kuo, CXCL12/CXCR4 promotes
laryngeal and hypopharyngeal squamous cell carcinoma metas-
tasis through MMP-13-dependent invasion via the ERK1/2/AP-1
pathway, Carcinogenesis 29 (2008) 1519–1527.
[35] S. Babykutty, P.P.S., N.R.J., M.A. Kumar, M.S. Nair, P. Srinivas, S.
Gopala, Nimbolide retards tumor cell migration, invasion, and
angiogenesis by downregulating MMP-2/9 expression via inhi-
biting ERK1/2 and reducing DNA-binding activity of NF-κB in
colon cancer cells, Mol. Carcinog. 51 (2012) 475–490.
[36] A.C. Borczuk, L. Gorenstein, K.L. Walter, A.A. Assaad, L. Wang, C.A.
Powell, Non-small-cell lung cancer molecular signatures recapi-
tulate lung developmental pathways, Am. J. Pathol. 163 (2003)
1949–1960.
[37] T.O. Nielsen, R.B. West, S.C. Linn, O. Alter, M.A. Knowling, J.X.
O'Connell, S. Zhu, M. Fero, G. Sherlock, J.R. Pollack, P.O. Brown, D.
Botstein, M. van de Rijn, Molecular characterisation of soft tissue
tumours: a gene expression study, Lancet 359 (2002) 1301–1307.
[38] M.A. Weterman, N. Ajubi, I.M. van Dinter, W.G. Degen, G.N. van
Muijen, D.J. Ruitter, H.P. Bloemers, Nmb, a novel gene, is
expressed in low-metastatic human melanoma cell lines and
xenografts, Int. J. Cancer 60 (1995) 73–81.
[39] C. Missale, F. Boroni, M. Losa, M. Giovanelli, A. Zanellato, R. Dal
Toso, A. Balsari, P.F. Spano, Nerve growth factor suppresses the
transforming phenotype of human prolactinomas, Proc. Natl.
Acad. Sci. USA 90 (1993) 7961–7975.
[40] M. Páez Pereda, C. Missale, Y. Grübler, E. Arzt, L. Schaaf, G.K.
Stalla, Nerve growth factor and retinoic acid inhibit proliferation
and invasion in thyroid tumor cells, Mol. Cell. Endocrinol. 167
(2000) 99–106.
[41] C. Missale, A. Codignola, S. Sigala, A. Finardi, M. Paez-Pereda, E.
Sher, P.F. Spano, Nerve growth factor abrogates the tumorigeni-
city of human small cell lung cancer cell lines, Proc. Natl. Acad.
Sci. USA 95 (1998) 5366–5371.
[42] C. Missale, M. Losa, S. Sigala, A. Balsari, M. Giovanelli, P.F. Spano,
Nerve growth factor controls proliferation and progression of
human prolactinoma cell lines through an autocrine mechanism,
Mol. Endocrinol. 10 (1996) 272–285.[43] C. Fiorentini, M. Facchetti, A. Finardi, S. Sigala, M. Páez-Pereda, E.
Sher, P.F. Spano, C. Missale, Nerve growth factor and retinoic acid
interactions in the control of small cell lung cancer proliferation,
Eur. J. Endocrinol. 147 (2002) 371–379.
[44] C.W. Graham, J.H. Lynch, D. Djakiew, Distribution of nerve
growth factor-like protein and nerve growth factor receptor in
human benign prostatic hyperplasia and prostatic adenocarci-
noma, J. Urol. 147 (1992) 1444–1447.
[45] M. Perez, T. Regan, B. Pﬂug, J. Lynch, D. Djakiew, Loss of low-
afﬁnity nerve growth factor receptor during malignant transfor-
mation of the human prostate, Prostate 30 (1997) 274–279.
[46] B. Pﬂug, D. Djakiew, Expression of p75NTR in a human prostate
epithelial tumor cell line reduces nerve growth factor-induced
cell growth by activation of programmed cell death, Mol.
Carcinog. 23 (1998) 106–114.
[47] A. Nalbandian, D. Djakiew, The p75(NTR) metastasis suppressor
inhibits urokinase plasminogen activator, matrix
metalloproteinase-2 and matrix metalloproteinase-9 in PC-3
prostate cancer cells, Clin. Exp. Metastasis 23 (2006) 107–116.
[48] A. Nalbandian, A.L. Pang, O.M. Rennert, W.Y. Chan, N. Ravindra-
nath, D. Djakiew, A novel function of differentiation revealed by
cDNA microarray proﬁling of p75NTR-regulated gene expression,
Differentiation 73 (2005) 385–396.
[49] J. Allen, F. Khwaja, D. Djakiew, Gene therapy of prostate
xenograft tumors with a p75NTR lipoplex, Anticancer Res. 24
(2004) 2997–3003.
[50] J. Allen, F. Khwaja, S. Byers, D. Djakiew, The p75NTR mediates a
bifurcated signal transduction cascade through the NF kappa B
and JNK pathways to inhibit cell survival, Exp. Cell Res. 304
(2005) 69–80.
[51] B.D. Carter, C. Kaltschmidt, B. Kaltschmidt, N. Offenhäuser, R.
Böhm-Matthaei, P.A. Baeuerle, Y.A. Barde, Selective activation of
NF-kappa B by nerve growth factor through the neurotrophin
receptor p75, Science 272 (1996) 542–545.
[52] C. Fiorentini, N. Guerra, M. Facchetti, A. Finardi, L. Tiberio, L.
Schiaffonati, P.F. Spano, C. Missale, Nerve growth factor regulates
dopamine D(2) receptor expression in prolactinoma cell lines via
p75(NGFR)-mediated activation of nuclear factor-kappaB, Mol.
Endocrinol. 16 (2002) 353–366.
[53] F. Driessler, K. Venstrom, R. Sabat, K. Asadullah, A.J. Schottelius,
Molecular mechanisms of interleukin-10-mediated inhibition of
NF-kappaB activity: a role for p50, Clin. Exp. Immunol. 135
(2004) 64–73.
[54] H. Zhong, M.J. May, E. Jimi, S. Ghosh, The phosphorylation status
of nuclear NF-kappa B determines its association with CBP/p300
or HDAC-1, Mol. Cell 9 (2002) 625–636.
[55] H. Guan, S. Hou, R.P. Ricciardi, DNA binding of repressor nuclear
factor-kappaB p50/p50 depends on phosphorylation of Ser337 by
the protein kinase A catalytic subunit, J. Biol. Chem. 280 (2005)
9957–9962.
[56] X. Messeguer, R. Escudero, D. Farré, O. Nuñez, J. Martínez, M.
Albà, PROMO: detection of known transcription regulatory ele-
ments using species-tailored searches, Bioinformatics 18 (2002)
333–334.
[57] D. Farré, R. Roset, M. Huerta, J.E. Adsuara, L. Roselló, M. Albà, X.
Messeguer, Identiﬁcation of patterns in biological sequences at
the ALGGEN server: PROMO and MALGEN, Nucleic Acids Res. 31
(2003) 3651–3653.
[58] M.H. Sheng, J.E. Wergedal, S. Mohan, K.H. Lau, Osteoactivin is a
novel osteoclastic protein and plays a key role in osteoclast
differentiation and activity, FEBS Lett. 582 (10) (2008)
1451–1458.
[59] S. Shikano, M. Bonkobara, P.K. Zukas, K. Ariizumi, Molecular
cloning of a dendritic cell-associated transmembrane protein,
DC-HIL, that promotes RGD-dependent adhesion of endothelial
cells through recognition of heparan sulfate proteoglycans, J. Biol.
Chem. 276 (11) (2001) 8125–8234.
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 3 ( 2 0 1 4 ) 1 0 0 – 1 11 111[60] H.Y. Naim, G. Joberty, M. Alfalah, R. Jacob, Temporal association
of the N- and O-linked glycosylation events and their implication
in the polarized sorting of intestinal brush border sucrase–
isomaltase, aminopeptidase N, and dipeptidyl peptidase IV,
J. Biol. Chem. 274 (1999) 17961–17967.
[61] J. Burchell, R. Poulsom, A. Hanby, C. Whitehouse, L. Cooper, H.
Clausen, D. Miles, J. Taylor-Papadimitriou, An alpha2,3 sialyl-
transferase (ST3Gal I) is elevated in primary breast carcinomas,
Glycobiology 9 (1999) 1307–1311.
[62] G. Morgia, M. Falsaperla, G. Malaponte, M. Madonia, M. Indeli-
cato, S. Travali, M.C. Mazzarino, Matrix metalloproteinases as
diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers
of prostate cancer, Urol. Res. 33 (2005) 44–50.
[63] M.A. Moses, D. Wiederschain, K.R. Loughlin, D. Zurakowski, C.C.
Lamb, M.R. Freeman, Increased incidence of matrix metallopro-
teinases in urine of cancer patients, Cancer Res. 58 (1998)
1395–1399.
[64] B. Brehmer, S. Biesterfeld, G. Jakse, Expression of matrix metal-
loproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and
-2) in prostate cancer tissue, Prostate Cancer Prostatic Dis. 6
(2003) 217–222.
[65] M. Wood, K. Fudge, J.L. Mohler, A.R. Frost, F. Garcia, M. Wang,
M.E. Stearns, In situ hybridization studies of metalloproteinases 2
and 9 and TIMP-1 and TIMP-2 expression in human prostate
cancer, Clin. Exp. Metastasis 15 (1997) 246–258.
[66] D. Trudel, Y. Fradet, F. Meyer, F. Harel, B. Têtu, Signiﬁcance of
MMP-2 expression in prostate cancer: an immunohistochemical
study, Cancer Res. 63 (2003) 8511–8515.
[67] O.H. Sanchez-Sweatman, F.W. Orr, G. Singh, Human metastatic
prostate PC3 cell lines degrade bone using matrix metallopro-
teinases, Invasion Metastasis 18 (1998) 297–305.
[68] M.W. Roomi, T. Kalinovsky, M. Rath, A. Niedzwiecki, Down-
regulation of urokinase plasminogen activator and matrix
metalloproteinases and up-regulation of their inhibitors by a
novel nutrient mixture in human prostate cancer cell lines PC-3
and DU-145, Oncol. Rep. 26 (2011) 1407–1413.
[69] C.A. London, H.S. Sekhon, V. Arora, D.A. Stein, P.L. Iversen, G.R.
Devi, A novel antisense inhibitor of MMP-9 attenuates angio-
genesis, human prostate cancer cell invasion and tumorigenicity,
Cancer Gene Ther. 10 (11) (2003) 823–832.
[70] A.K. Nalla, B. Gorantla, C.S. Gondi, S.S. Lakka, J.S. Rao, Targeting
MMP-9, uPAR, and cathepsin B inhibits invasion, migration and
activates apoptosis in prostate cancer cells, Cancer Gene Ther. 17
(9) (2010) 599–613.[71] W.D. Zhong, Z.D. Han, H.C. He, X.C. Bi, Q.S. Dai, G. Zhu, Y.K. Ye, Y.X.
Liang, W.J. Qin, Z. Zhang, G.H. Zeng, Z.N. Chen, CD147, MMP-1,
MMP-2 and MMP-9 protein expression as signiﬁcant prognostic
factors in human prostate cancer, Oncology 75 (2008) 230–236.
[72] S. Escaff, J.M. Fernández, L.O. González, A. Suárez, S. González-
Reyes, J.M. González, F.J. Vizoso, Study of matrix metalloprotei-
nases and their inhibitors in prostate cancer, Br. J. Cancer 102
(2010) 922–929.
[73] N. Nonsrijun, J. Mitchai, K. Brown, R. Leksomboon, P. Tuamsuk,
Overexpression of matrix metalloproteinase 11 in thai prostatic
adenocarcinoma is associated with poor survival, Asian Pac.
J. Cancer Prev. 14 (2013) 3331–3335.
[74] D.E. Gomez, D.F. Alonso, H. Yoshiji, U.P. Thorgeirsson, Tissue
inhibitors of metalloproteinases: structure, regulation and
biological functions, Eur. J. Cell Biol. 74 (1997) 111–122.
[75] K. Brew, H. Nagase, The tissue inhibitors of metalloproteinases
(TIMPs): an ancient family with structural and functional diver-
sity, Biochim. Biophys. Acta 1803 (2010) 55–71.
[76] L.T. Zhou, F.Y. Liu, Y. Li, Y.M. Peng, Y.H. Liu, J. Li, Gpnmb/
osteoactivin, an attractive target in cancer immunotherapy,
Neoplasma 59 (2012) 1–5.
[77] M. Tomihari, J.S. Chung, H. Akiyoshi, P.D. Cruz Jr., K. Ariizumi,
DC-HIL/glycoprotein Nmb promotes growth of melanoma in
mice by inhibiting the activation of tumor-reactive T cells, Cancer
Res. 70 (2010) 5778–5787.
[78] X. Qian, E. Mills, M. Torgov, W.J. LaRochelle, M. Jeffers, Pharma-
cologically enhanced expression of GPNMB increases the sensi-
tivity of melanoma cells to the CR011-vcMMAE antibody–drug
conjugate, Mol. Oncol. 2 (2008) 81–93.
[79] V.A. Pollack, E. Alvarez, K.F. Tse, M.Y. Torgov, S. Xie, S.G. Shenoy, J.
R. MacDougall, S. Arrol, H. Zhong, R.W. Gerwien, W.F. Hahne, P.D.
Senter, M.E. Jeffers, H.S. Lichenstein, W.J. LaRochelle, Treatment
parameters modulating regression of human melanoma xeno-
grafts by an antibody–drug conjugate (CR011-vcMMAE) targeting
OA, Cancer Chemother. Pharmacol. 60 (2007) 423–435.
[80] L. Naumovski, J.R. Junutula, Glembatumumab vedotin, a conju-
gate of an anti-glycoprotein non-metastatic melanoma protein B
mAb and monomethyl auristatin E for the treatment of mela-
noma and breast cancer, Curr. Opin. Mol. Ther. 12 (2010)
248–257.
[81] C.H. Keir, L.T. Vahdat, The use of an antibody drug conjugate,
glembatumumab vedotin (CDX-011), for the treatment of breast
cancer, Expert Opin. Biol. Ther. 12 (2012) 259–263.
